Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases.
Severe graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). However, there have been only a few limited therapeutic options for the treatment of GVHD. Here we have reported two cases of the patients with acute steroid-refractory GVHD who underwent allogeneic HSCT. These patients received infusions of third-party clonal mesenchymal stem cells (cMSCs), which were isolated by a subfractionation culturing method (SCM) developed recently by our group, and showed marked improvement of the disease. MSCs represent a new potential therapeutic option in the treatment of steroid-refractory acute GVHD. They showed safety and improved clinical findings of the acute GVHD patients. However, further investigations are needed to understand the accurate mechanisms of MSCs and larger well-designed human clinical trials are necessary to prove further the safety and efficacy of the cMSCs for the treatment of acute GVHD patients.
Lim
Joo Han
JH
Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
Lee
Moon Hee
MH
Yi
Hyeon Gyu
HG
Kim
Chul Soo
CS
Kim
Jun Hyung
JH
Song
Sun U
SU
D000293:Adolescent; D004351:Drug Resistance; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D008875:Middle Aged; D013256:Steroids / Q000494:pharmacology / Q000627:therapeutic use; D017154:Stromal Cells; D016896:Treatment Outcome
D013256:Steroids